Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind trial of NS-863 in pulmonary arterial hypertension
jRCT2031260222Phase 2Not yet recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of NS-863 in pulmonary arterial hypertension (PAH) (3 arms), sponsored by NS Pharma, Inc. Primary endpoints: Change in pulmonary vascular resistance (PVR) and Adverse events. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
NS-863
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2031260222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260222.